Circulating Glycan Monosaccharide Composite-Based Biomarker Diagnoses Colorectal Cancer at Early Stages and Predicts Prognosis

Hsa_circ_0124554 may serve as a biomarker for the diagnosis of colorectal cancer: An observational study

Circular RNAs (circRNAs) play important roles in the occurrence and development of cancer, and have been shown with diagnostic values in various cancers. The latest research showed that hsa_circ_0124554 is closely related to liver metastasis and vascular invasion in colorectal cancer (CRC). This study aimed to investigate whether hsa_circ_0124554 can be used as a diagnostic marker for CRC. In this study, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to detect hsa_circ_0124554 expression levels in 40 pairs of CRC tissues and adjacent non-tumor intestinal tissues derived from CRC patients and 32 paired plasma specimens. The relationship between the expression of hsa_circ_0124554 and the clinicopathological features of CRC patients was analyzed by t-test and chi-square test. Receiver operating characteristic (ROC) curve analysis was established to explore the diagnostic value of hsa_circ_0124554 in CRC. The results showed that hsa_circ_0124554 was substantially expressed in CRC tissues (P < .001) and that there were variations in pathological differentiation, perineural invasion and invasion. The expression of hsa_circ_0124554 in CRC patients was considerably higher than healthy controls (P < .001). The area under the receiver operating characteristic (ROC) curve (AUC) of tissue and plasma hsa_circ_0124554 was 0.703 and 0.742. The AUC of the expression combined hsa_circ_0124554, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) had the best diagnostic performance (AUC = 0.899) in the CRC groups, and the sensitivity and specificity were 0.844 and 0.844. The expression of hsa_circ_0124554 was up-regulated in the tissues and plasma in CRC patients, which may be a new biomarker for the diagnosis of CRC. The combination hsa_circ_0124554, CEA and CA199 has the best diagnostic efficacy in CRC.

HPLC for simultaneous quantification of free mannose and glucose concentrations in serum: use in detection of ovarian cancer

Background: Abnormal levels of monosaccharides in blood have been linked to tumorigenesis. In this study, a novel high-performance liquid chromatography (HPLC) method was established for the simultaneous determination of free mannose and glucose in the serum. Methods: The serum was directly derivatized by 1-phenyl-3-methyl-5-pyrazolone under alkaline conditions using L-rhamnose as an internal standard. The chromatographic separation was then performed on a Poroshell EC-C18 chromatographic column (4.6 × 100 mm, particle size 2.7 μm, Agilent) with gradient elution using NH4Ac-HAc and acetonitrile as the mobile phases. The method was thereafter validated according to international guidelines. The serum samples obtained from 200 healthy individuals and 200 ovarian cancer (OC) patients were analyzed for free mannose and glucose. Results: The method was found to be reproducible for quantification within 20 min and included online sample purification. The method displayed excellent linearity in the concentration range (for mannose: 0.5-500 μg/mL; glucose: 0.5-1500 μg/mL). The precision, recovery, and stability met the FDA bioanalytical method validation acceptance criteria. Overall, the measurement of glucose content by HPLC correlated well with the different enzymatic methods. Ovarian cancer mannose levels in the serum were significantly higher in the advanced stage (61.22 μmol/L, p < 0.0001) than those in healthy volunteers and early-stage patients (44.51 μmol/L versus 50.09 μmol/L, p < 0.0001). The AUC for the ratio of serum free glucose to mannose (G/M) was 0.98 (p < 0.0001), with a sensitivity of 91.46% and a specificity of 98.50%, which served as a biomarker for OC diagnosis. Conclusion: We report a simple, repeatable, and attractive analytical method by HPLC, which can be used for quantitative estimation of free mannose and glucose simultaneously in human serum. Our results indicate that the serum level of mannose could be used as a potential biomarker of ovarian cancer.

Determination of monosaccharide composition in human serum by an improved HPLC method and its application as candidate biomarkers for endometrial cancer

Altered glycan levels in serum have been associated with increased risk of cancer. In this study, we have developed and validated a HPLC-based method to analyze monosaccharide composition (D-mannose, Glucosamine, Galactosamine, Glucuronic acid, D-glucose, D-galactose, D-xylose, L-fucose) in human serum, with L-rhamnose, being used as internal standard. Monosaccharides obtained from hydrolyzed serum samples were derivatized by 1-Phenyl-3-methyl-5-pyrazolone. A ZORBAX XDB-C18 column(150×4.6mm) was used for chromatographic separation with 100 mM ammonium acetate buffer (NH4Ac-HAc, PH=5.5, solvent A), acetonitrile (ACN, solvent B) as a mobile phase. The calibration standard curves for the eight monosaccharides showed good linearity over the range of 2.5-500μg/mL with R² > 0.995. The relative standard deviation values for intra-day and inter-day precision were ≤ 5.49%. Recovery was 69.01-108.96%. We observed that this column exhibited high specificity and selectivity to separate monosaccharides from serum. This method was then applied to quantitatively analyze the serum monosaccharide levels in 30 patients with endometrial cancer and 30 matched healthy controls. Statistical analysis indicated that the serum monosaccharide levels were significantly higher in patients compared with healthy controls (P value< 0.0001). Overall, we report here a simple, reliable, low-cost, and reproducible HPLC method for the separation and quantification monosaccharides in the human serum, which has potential value to serve as a screening marker for endometrial cancer.